keyword
MENU ▼
Read by QxMD icon Read
search

lewy body dementia review

keyword
https://www.readbyqxmd.com/read/29780858/can-visuospatial-measures-improve-the-diagnosis-of-alzheimer-s-disease
#1
REVIEW
Shirin Salimi, Muireann Irish, David Foxe, John R Hodges, Olivier Piguet, James R Burrell
Introduction: Overlapping and evolving symptoms lead to ambiguity in the diagnosis of dementia. Visuospatial function relies on parietal lobe function, which may be affected in the early stages of Alzheimer's disease (AD). This review evaluates visuospatial dysfunction in patients with AD, frontotemporal dementia, dementia with Lewy bodies, and vascular dementia to determine the diagnostic and prognostic potential of visuospatial tasks in AD. Methods: A systematic search of studies (1960-2016) investigating visuospatial dysfunction in dementia was conducted...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29761296/neuroimaging-in-lewy-body-dementia
#2
REVIEW
Tayyabah Yousaf, George Dervenoulas, Polytimi-Eleni Valkimadi, Marios Politis
Lewy body dementia (DLB) is a common form of cognitive impairment, accounting for 30% of dementia cases in ages over 65 years. Early diagnosis of DLB has been challenging; particularly in the context of differentiation with Parkinson's disease dementia and other forms of dementias, such as Alzheimer's disease and rapidly progressive dementias. Current practice involves the use of [123 I]FP-CIT-SPECT, [18 F]FDG PET and [123 I]MIBG molecular imaging to support diagnostic procedures. Structural imaging techniques have an essential role for excluding structural causes, which could lead to a DLB-like phenotype, as well as aiding differential diagnosis through illustrating disease-specific patterns of atrophy...
May 14, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29758938/influence-of-lewy-pathology-on-alzheimer-s-disease-phenotype-a-retrospective-clinico-pathological-study
#3
Jennifer Roudil, Vincent Deramecourt, Boris Dufournet, Bruno Dubois, Mathieu Ceccaldi, Charles Duyckaerts, Florence Pasquier, Thibaud Lebouvier
BACKGROUND: Studies have shown the frequent coexistence of Lewy pathology (LP) in AD. OBJECTIVE: The aim of this study was to determine the influence of LP on the clinical and cognitive phenotype in a cohort of patients with a neuropathological diagnosis of AD. METHODS: We reviewed neuropathologically proven AD cases, reaching Braak stages V and VI in the brain banks of Lille and Paris between 1993 and 2016, and classified them according to LP extension (amygdala, brainstem, limbic, or neocortical)...
May 11, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29746400/mri-of-non-alzheimer-s-dementia-current-and-emerging-knowledge
#4
Massimo Filippi, Federica Agosta
PURPOSE OF REVIEW: The correct classification of non-Alzheimer's dementia is crucial to study disease mechanisms, predict disease progression and test disease-specific treatments. Brain atrophy assessment with morphometric MRI is currently the gold standard for in-vivo localization of neurodegeneration. Structural and functional connectivity biomarkers are becoming increasingly available. This review emphasizes the potential applications of MRI in the main non-Alzheimer's dementia such as dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD)...
May 8, 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29742332/clinical-features-of-auditory-hallucinations-in-patients-with-dementia-with-lewy-bodies-a-soundtrack-of-visual-hallucinations
#5
Naoko Tsunoda, Mamoru Hashimoto, Tomohisa Ishikawa, Ryuji Fukuhara, Seiji Yuki, Hibiki Tanaka, Yutaka Hatada, Yusuke Miyagawa, Manabu Ikeda
OBJECTIVE: Auditory hallucinations are an important symptom for diagnosing dementia with Lewy bodies (DLB), yet they have received less attention than visual hallucinations. We investigated the clinical features of auditory hallucinations and the possible mechanisms by which they arise in patients with DLB. METHODS: We recruited 124 consecutive patients with probable DLB (diagnosis based on the DLB International Workshop 2005 criteria; study period: June 2007-January 2015) from the dementia referral center of Kumamoto University Hospital...
May 8, 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29738880/the-interaction-of-%C3%AE-synuclein-and-tau-a-molecular-conspiracy-in-neurodegeneration
#6
REVIEW
Xu Yan, Riikka-Liisa Uronen, Henri J Huttunen
α-synuclein and Tau are proteins prone to pathological misfolding and aggregation that are normally found in the presynaptic and axonal compartments of neurons. Misfolding initiates a homo-oligomerization and aggregation cascade culminating in cerebral accumulation of aggregated α-synuclein and Tau in insoluble protein inclusions in multiple neurodegenerative diseases. Traditionally, α-synuclein-containing Lewy bodies have been associated with Parkinson's disease and Tau-containing neurofibrillary tangles with Alzheimer's disease and various frontotemporal dementia syndromes...
May 5, 2018: Seminars in Cell & Developmental Biology
https://www.readbyqxmd.com/read/29734182/a-systematic-review-and-meta-analysis-of-the-effectiveness-of-acetylcholinesterase-inhibitors-and-memantine-in-treating-the-cognitive-symptoms-of-dementia
#7
Ruth Knight, Mizanur Khondoker, Nicholas Magill, Robert Stewart, Sabine Landau
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2...
May 7, 2018: Dementia and Geriatric Cognitive Disorders
https://www.readbyqxmd.com/read/29720959/role-of-neuroimaging-as-a-biomarker-for-neurodegenerative-diseases
#8
REVIEW
Soichiro Shimizu, Daisuke Hirose, Hirokuni Hatanaka, Naoto Takenoshita, Yoshitsugu Kaneko, Yusuke Ogawa, Hirofumi Sakurai, Haruo Hanyu
It has recently been recognized that neurodegenerative diseases are caused by common cellular and molecular mechanisms including protein aggregation and inclusion body formation. Each type of neurodegenerative disease is characterized by the specific protein that aggregates. In these days, the pathway involved in protein aggregation has been elucidated. These are leading to approaches toward disease-modifying therapies. Neurodegenerative diseases are fundamentally diagnosed pathologically. Therefore, autopsy is essential for a definitive diagnosis of a neurodegenerative disease...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29686602/advancing-stem-cell-models-of-alpha-synuclein-gene-regulation-in-neurodegenerative-disease
#9
REVIEW
Desiree A Piper, Danuta Sastre, Birgitt Schüle
Alpha-synuclein ( non A4 component of amyloid precursor, SNCA, NM_000345.3 ) plays a central role in the pathogenesis of Parkinson's disease (PD) and related Lewy body disorders such as Parkinson's disease dementia, Lewy body dementia, and multiple system atrophy. Since its discovery as a disease-causing gene in 1997, alpha-synuclein has been a central point of scientific interest both at the protein and gene level. Mutations, including copy number variants, missense mutations, short structural variants, and single nucleotide polymorphisms, can be causative for PD and affect conformational changes of the protein, can contribute to changes in expression of alpha-synuclein and its isoforms, and can influence regulation of temporal as well as spatial levels of alpha-synuclein in different tissues and cell types...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29684335/emergence-of-breath-testing-as-a-new-non-invasive-diagnostic-modality-for-neurodegenerative-diseases
#10
REVIEW
N Siva Subramaniam, C S Bawden, H Waldvogel, R M L Faull, G S Howarth, R G Snell
Neurodegenerative diseases (NDDs) are incapacitating disorders that result in progressive motor and cognitive impairment. These disease include Alzheimer's disease the most common cause of dementia, frontotemporal dementia, amyotrophic lateral sclerosis, dementia with Lewy bodies, Parkinson's, Huntington's, Friedreich's ataxia, and prion disease. Dementia causing NDDs impose a high social and economic burden on communities around the world. Rapid growth in knowledge regarding the pathogenic mechanisms and disease-associated biomarkers of these diseases in the past few decades have accelerated the development of new diagnostic methods and therapeutic opportunities...
April 20, 2018: Brain Research
https://www.readbyqxmd.com/read/29664058/relationships-between-rapid-eye-movement-sleep-behavior-disorder-and-neurodegenerative-diseases-clinical-assessments-biomarkers-and-treatment
#11
REVIEW
Min Li, Li Wang, Jiang-Hong Liu, Shu-Qin Zhan
Objective: Rapid eye movement sleep behavior disorder (RBD) is characterized by dream enactment and loss of muscle atonia during rapid eye movement sleep. RBD is closely related to α-synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Many studies have investigated the markers of imaging and neurophysiological, genetic, cognitive, autonomic function of RBD and their predictive value for neurodegenerative diseases. This report reviewed the progress of these studies and discussed their limitations and future research directions...
April 20, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29658429/color-vision-impairment-differentiates-alzheimer-dementia-from-dementia-with-lewy-bodies
#12
Patrick M Flanigan, Mitra A Khosravi, James B Leverenz, Babak Tousi
OBJECTIVE: Dementia with Lewy bodies (DLB) is frequently misdiagnosed for Alzheimer dementia (AD), especially in its earlier stages. We characterized color vision impairment (CVI) in patients with DLB versus patients with AD to determine its usefulness in improving accuracy of early diagnosis. METHODS: We retrospectively reviewed charts of patients with AD, DLB, and patients with mild cognitive impairment suspected to be in the prodromal phase of DLB (pro-DLB) or prodromal phase of AD (pro-AD)...
March 2018: Journal of Geriatric Psychiatry and Neurology
https://www.readbyqxmd.com/read/29657900/occipital-and-cingulate-hypometabolism-are-significantly-under-reported-on-18-fluorodeoxyglucose-positron-emission-tomography-scans-of-patients-with-lewy-body-dementia
#13
Moath Hamed, Frank Schraml, Jeffrey Wilson, James Galvin, Marwan N Sabbagh
Objective: To determine whether occipital and cingulate hypometabolism is being under-reported or missed on 18-fluorodeoxyglucose positron emission tomography (FDG-PET) CT scans in patients with Dementia with Lewy Bodies (DLB). Background: Recent studies have reported higher sensitivity and specificity for occipital and cingulate hypometabolism on FDG-PET of DLB patients. Methods: This retrospective chart review looked at regions of interest (ROI's) in FDG-PET CT scan reports in 35 consecutive patients with a clinical diagnosis of probable, possible, or definite DLB as defined by the latest DLB Consortium Report...
2018: Journal of Alzheimer's Disease and Parkinsonism
https://www.readbyqxmd.com/read/29616607/non-pharmacological-interventions-for-persons-with-dementia-what-are-they-and-how-should-they-be-studied
#14
Jiska Cohen-Mansfield
The publication of four papers concerning non-pharmacological interventions for persons with dementia heralds progress in the science of dementia care. The four papers are very diverse in focus and methodology, and include a study of the impact of a visual arts program on quality of life, communication, and well-being by Windle et al. (2017); an overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia by Dyer et al...
March 2018: International Psychogeriatrics
https://www.readbyqxmd.com/read/29610549/biochemical-properties-of-cholesterol-aldehyde-secosterol-and-its-derivatives
#15
REVIEW
Noriyuki Miyoshi
Elevated levels of cholesterol aldehyde, 3β-hydroxy-5-oxo-5,6-secocholestan-6-al (secosterol-A, also called 5,6-secosterol), and its aldolization product (secosterol-B) have been detected in human atherosclerotic plaques and tissues samples of brains affected by neurodegeneration, such as Alzheimer's disease and Lewy body dementia suggesting that increased formation of these compounds may be associated with inflammation-related diseases. Secosterol-A and secosterol-B, and also further oxidized products seco-A-COOH and seco-B-COOH induce several pro-inflammatory activities in vitro ...
March 2018: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/29593630/parkinson-s-disease-dementia-and-dementia-with-lewy-bodies-have-similar-neuropsychological-profiles
#16
Georgina M Aldridge, Allison Birnschein, Natalie L Denburg, Nandakumar S Narayanan
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are common causes of dementia worldwide. Although considered separate entities based on the relative temporal onset of motor symptoms vs. diagnosis of dementia, it is unknown if these diseases truly have distinct cognitive profiles. We hypothesized that patients divided into PDD and DLB categories strictly by temporal criteria would have different neuropsychological profiles. We investigated this question via neuropsychological testing of PDD and DLB patients at the University of Iowa...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29569570/behavioral-and-psychological-symptoms-in-lewy-body-disease-a-review
#17
Lucie Jurek, Mathieu Herrmann, Mathilde Bonze, Sophie Brunet, Catherine Padovan, Jean-Michel Dorey
Dementia with Lewy bodies (DLB) is a common neurodegenerative disease, second in terms of prevalence after Alzheimer's disease (AD). DLB may be suspected according to three core features which are cognitive and motor fluctuations, early visual hallucinations and parkinsonism; and more recently, according to the new criteria, REM sleep behavior disorder (RBD). Behavorial and psychological symptoms associated with DLB are more frequent, more severe and appear earlier than those found in other neurodegenerative diseases...
March 1, 2018: Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
https://www.readbyqxmd.com/read/29550847/-123-i-ioflupane-spet-and-123-i-mibg-in-the-diagnosis-of-parkinson-s-disease-and-parkinsonian-disorders-and-in-the-differential-diagnosis-between-alzheimer-s-and-lewy-s-bodies-dementias
#18
REVIEW
Susanna Nuvoli, Barbara Palumbo, Simona Malaspina, Giuseppe Madeddu, Angela Spanu
Nuclear medicine procedures are widely used as "in vivo" biomarkers in a large number of brain diseases, especially in the diagnosis of Parkinson's disease (PD) and of parkinsonian disorders (pD). Furthermore, nuclear medicine is used in the differential diagnosis of dementias especially Alzheimer's disease (AD) and dementia with Lewy's bodies (LBD) which share many clinical symptoms and often LBD is misdiagnosed as AD. The differential diagnosis between these clinical entities is crucial for treatment since LBD also shares some clinical symptoms with parkinsonian disorders...
January 2018: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29508456/autonomic-dysfunction-in-genetic-forms-of-synucleinopathies
#19
REVIEW
Viorica Chelban, Ekawat Vichayanrat, Lucia Schottlaende, Valeria Iodice, Henry Houlden
The discovery of genetic links between alpha-synuclein and PD has opened unprecedented opportunities for research into a new group of diseases, now collectively known as synucleinopathies. Autonomic dysfunction, including cardiac sympathetic denervation, has been reported in familial forms of synucleinopathies that have Lewy bodies at the core of their pathogenesis. SNCA mutations and multiplications, LRRK2 disease with Lewy bodies as well as other common, sporadic forms of idiopathic PD, MSA, pure autonomic failure, and dementia with Lewy bodies have all been associated with dysautonomia...
March 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29508455/treatment-of-autonomic-dysfunction-in-parkinson-disease-and-other-synucleinopathies
#20
REVIEW
Jose-Alberto Palma, Horacio Kaufmann
Dysfunction of the autonomic nervous system afflicts most patients with Parkinson disease and other synucleinopathies such as dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, reducing quality of life and increasing mortality. For example, gastrointestinal dysfunction can lead to impaired drug pharmacodynamics causing a worsening in motor symptoms, and neurogenic orthostatic hypotension can cause syncope, falls, and fractures. When recognized, autonomic problems can be treated, sometimes successfully...
March 2018: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
61615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"